Zacks Research Downgrades Astellas Pharma (OTCMKTS:ALPMY) to Hold

Astellas Pharma (OTCMKTS:ALPMY – Get Free Report) was downgraded by stock analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Wednesday,Zacks.com reports.

Separately, Jefferies Financial Group raised Astellas Pharma from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 24th. One investment analyst has rated the stock with a Strong Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold”.

Get Astellas Pharma alerts:

Read Our Latest Stock Report on Astellas Pharma

Astellas Pharma Stock Performance

OTCMKTS:ALPMY opened at $13.09 on Wednesday. The firm’s 50-day moving average is $13.51 and its 200-day moving average is $14.64. The company has a market cap of $23.69 billion, a price-to-earnings ratio of 12.19 and a beta of 0.07. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.90 and a current ratio of 1.17. Astellas Pharma has a 52-week low of $9.91 and a 52-week high of $17.35.

Astellas Pharma (OTCMKTS:ALPMY – Get Free Report) last issued its quarterly earnings results on Monday, April 27th. The company reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.14. Astellas Pharma had a return on equity of 23.54% and a net margin of 13.66%.The firm had revenue of $3.38 billion for the quarter, compared to analyst estimates of $3.28 billion. Equities research analysts anticipate that Astellas Pharma will post 1.25 earnings per share for the current year.

Astellas Pharma Company Profile

(Get Free Report)

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).

Further Reading

• Five stocks we like better than Astellas Pharma
• Microsoft Earnings Are Coming—But Azure and CapEx Will Decide the Reaction
• Premium Retail’s Stress Test Is Separating Winners From Losers
• D-Wave Quantum or a Quantum ETF: Which Is the Better Bet?
• GE Vernova Just Sent a Mixed AI Signal to Investors

Receive News & Ratings for Astellas Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astellas Pharma and related companies with MarketBeat.com's FREE daily email newsletter.